A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.

Trial Profile

A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Ublituximab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors TG Therapeutics Inc
  • Most Recent Events

    • 09 Aug 2017 According to a TG Therapeutics media release, the company expects to present updated clinical data from this trial in 2017.
    • 27 Jun 2017 Preliminary results (n=23) assessing optimal dose and infusion time as well as safety and tolerability, presented at the 3rd Congress of the European Academy of Neurology.
    • 26 Jun 2017 Results (n=24) presented at the 3rd Congress of the European Academy of Neurology (EAN), according to a TG Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top